Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Journal of Clinical Medicine · 21.12.2025 · 15 (1) · 50
DOI: 10.3390/jcm15010050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.12.2025. Verfasst von Abir Alsaid und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Department of Internal Medicine, King Fahd Hospital of the University, Al Khobar 31952, Saudi Arabia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in patients with type 2 diabetes (T2D), and advanced fibrosis is the strongest predictor of liver-related morbidity and mortality. Therefore, early noninvasive risk stratification is critical. While the Fibrosis-4 (FIB-4) index and vibration-controlled transient elastography (VCTE) are widely used, the newer FibroScan-AST (FAST) score has shown promise in detecting at-risk metabolic-associated steatohepatitis (MASH) with significant fibrosis. Evidence comparing the FAST and FIB-4 indices in Middle Eastern T2D populations remains limited. We compared the diagnostic performances of these models for advanced fibrosis in Saudi patients with T2D and MASLD.
Methods
We conducted a retrospective analysis of 273 patients diagnosed with T2D and MASLD. All patients underwent VCTE. To identify advanced fibrosis, we used liver stiffness measurement (LSM) as a surrogate marker for liver biopsy. We calculated the FAST and FIB-4 indices for each patient. To assess the diagnostic performance of these scores, we evaluated their sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUROC).
Results
In this cohort study, 26.4% of participants had a high-risk FAST score (>0.35; median: 0.13). Patients with high-risk FAST scores (>0.35) were younger, had higher BMIs, elevated liver enzyme levels, and poorer glycemic control than those in the lower-risk groups. High-risk FAST scores were strongly correlated with elevated LSM, FIB-4, and controlled attenuation parameter values (p < 0.001). The FAST score demonstrated better performance than the FIB-4 index in detecting advanced fibrosis. It showed higher accuracy (85.4% vs. 77.3%), sensitivity (82.0% vs. 48.0%), and negative predictive value (95.5% vs. 87.8%) while maintaining a similar specificity. The AUROC values were 0.936 (95% CI: 0.901–0.971) for the FAST score compared to 0.711 (95% CI: 0.625–0.797) for the FIB-4 index.
Conclusions
The FAST score demonstrated better diagnostic accuracy than the FIB-4 index and identified patients with poor metabolic control and obesity as being at the highest risk among Saudi patients with T2D and MASLD. These findings support the integration of other elastography-based tests into stepwise fibrosis screening pathways for diabetic populations, potentially improving the early detection of advanced fibrosis and patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary, Department of Internal Medicine, King Fahd Hospital of the University, Al Khobar 31952, Saudi Arabia.
- College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
- Division of Endocrine, Department of Internal Medicine, King Fahd Hospital of the University, Al Khobar 31952, Saudi Arabia.
- Division of Gastroenterology, Department of Internal Medicine, King Fahd Hospital of the University, Al Khobar 31952, Saudi Arabia.
- Department of Anesthesia, King Fahd Hospital of the University, Al Khobar 31952, Saudi Arabia.
ORCID-Profile: Reem J Al Argan, Abdullah Alotaibi, Mona H Ismail
Zitieren
APA
Alsaid, A., Al Argan, R. J., Elamin, Y. A., Alshiekh, N., Hassan, A., Alotaibi, A., Gaarour, I., & Ismail, M. H. (2025). Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine, 15(1), 50. https://doi.org/10.3390/jcm15010050
Vancouver
Alsaid A, Al Argan RJ, Elamin YA, Alshiekh N, Hassan A, Alotaibi A, et al. Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine. 2025;15(1):50. doi:10.3390/jcm15010050
BibTeX
@article{Alsaid2025,
author = {Alsaid, Abir and Al Argan, Reem J and Elamin, Yasir A and Alshiekh, Nora and Hassan, Amna and Alotaibi, Abdullah and Gaarour, Ihab and Ismail, Mona H},
title = {Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {15},
number = {1},
pages = {50},
doi = {10.3390/jcm15010050}
}
EUVIMED